Purpose: To compare variable dose-rate volumetric modulated arc therapy (VMAT) with 7-field, step-and-shoot intensity modulated radiation therapy (IMRT) in prostate cancer patients treated with a consistent planning target volume (PTV) to a uniform total radiation therapy dose.
Methods And Materials: We studied 32 patients who received 8100 cGy in 45 daily fractions to their prostate and proximal 1 cm of the seminal vesicles using variable dose rate VMAT (n = 22) or 7-field, step-and-shoot IMRT (n = 10) for intermediate-risk or high-risk prostate cancer between July 2010 and April 2013. In 90% of patients, VMAT was delivered with 2 arcs. To have an unbiased comparison of plan quality, patients who were treated with VMAT were also planned with IMRT and vice versa. Each patient served as his own control for the comparison.
Results: VMAT reduced median radiation beam-on time from 4.3 to 3.4 minutes (P = .03). There was no statistically significant difference in PTV volumes between the VMAT and step-and-shoot IMRT groups (P = .76). VMAT dose distributions were more homogeneous (P = .003). There was no difference between groups with regard to rectal V60, V65, V70, V75, bladder V65, V70, V75, V80, or femoral heads V33.
Conclusions: Two-arc VMAT resulted in shorter beam-on times and more homogenous dose distributions than 7-field, step-and-shoot IMRT for prostate cancer. With decreased beam-on time, the intrafraction motion during irradiation is reduced, thus improving confidence that the delivered dose distribution agrees with the plan.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.prro.2014.03.003 | DOI Listing |
Cell Mol Biol (Noisy-le-grand)
January 2025
Al Door Technical Institute, Northern Technical University, Mosul, Iraq.
Prostate cancer is the most common type after the age of fifty. It affects males and affects the prostate gland, which protects the function of sperm by producing semen. The current study was designed to evaluate prostate cancer infection effects on some biomarkers such as irisin, Tumor necrosis factor-TNF-α, prostate acid phosphates -PAP, Glutathione-GSH, malondialdehyde-MDA, urea, and creatinine.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
January 2025
Departamento de Biología Molecular y Genómica y Departamento de Disciplinas Filosófico Metodológicas e Instrumentales. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
ABCG2 transporter protein is one of several markers of prostate cancer stem cells (PCSCs). Gene variants of ABCG2 could affect protein expression, function, or both. The aim of this study was to identify the genetic variability of the ABCG2 gene in Mexican patients with prostate cancer.
View Article and Find Full Text PDFJ Cell Mol Med
January 2025
Department of Medical Biology, Faculty of Medicine, Kutahya Health Sciences University, Kutahya, Turkey.
Chemotherapy is a potent tool against cancer, but drug resistance remains a major obstacle. To combat this, understanding the molecular mechanisms behind resistance in cancer cells and the protein expression changes driving these mechanisms is crucial. Targeting the Ubiquitin-Proteasome System (UPS) has proven effective in treating multiple myeloma and shows promise for solid tumours.
View Article and Find Full Text PDFEur Urol
January 2025
Eastern Health Clinical School, Monash University, Melbourne, Australia; Cancer Services, Eastern Health, Melbourne, Australia; Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia.
Eur Urol
January 2025
Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; "Vita-Salute" San Raffaele University, Milan, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!